Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
RESEARCH TOOLSreports
Holding PHAT?
Track your performance easily
PHAT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.07 - $19.71
Previous Close$16.05
Volume1.11M
Average Volume (3M)964.77K
Market Cap
$1.10B
Enterprise Value$995.09M
Total Cash (Recent Filing)$276.24M
Total Debt (Recent Filing)$175.28M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 06, 2024EPS Estimate
-$1.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.13
Shares Outstanding68,290,000
10 Day Avg. Volume1,024,326
30 Day Avg. Volume964,775
Standard Deviation0.20
R-Squared0.03
Alpha0.00710
Financial Highlights & Ratios
Price to Book (P/B)-4.69
Price to Sales (P/S)110.51
Price to Cash Flow (P/CF)-3.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue100.33
Enterprise Value/Gross Profit1.93K
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$22.00Price Target Upside37.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Phathom Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Commercial CoverageCommercial coverage for Voquezna had increased to about 77%, indicating a significant improvement in access and availability.
Prescription GrowthVoquezna prescriptions grew sequentially by over 265%, reaching more than 35,000 filled prescriptions compared to approximately 9,500 previously.
Product LaunchVoquezna reflects the first novel innovation in GERD in over 30 years, challenging standard-of-care proton pump inhibitor limitations with its novel rapid, potent, and durable profile.
Bears Say
Commercial TrendsNormalization of commercial trends and stocking dynamics is needed before gaining confidence in the stock's potential.
Growth EvidenceAdditional evidence of a growth inflection in TRx is awaited, which could delay positive sentiment towards the stock.
Investor FocusInvestor attention is expected to focus primarily on improving patient access, which may impact stock perception.
---
Ownership Overview
18.30% Insiders
9.38% Mutual Funds
11.06% Other Institutional Investors
52.90% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $6.07 and its highest was $19.71 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Currently, no data Available
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is Nov 06, 2024 which is in 5 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Aug 08, 2024. The company reported -$1.56 earnings per share for the quarter, missing the consensus estimate of -$1.32 by -$0.24.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -$1.47.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 68,289,620 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$1.56 in its last earnings report, missing expectations of -$1.32. Following the earnings report the stock price went up 8.696%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Among the largest hedge funds holding Phathom Pharmaceuticals’s share is Gilder Gagnon Howe & Co LLC.. It holds Phathom Pharmaceuticals’s shares valued at 15M.
---
Phathom Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (37.07% Upside)
$22.00 (37.07% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 888.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
20.50%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. It develops Vonoprazan, a potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Buffalo Grove, IL.
---
PHAT Earnings Call
Q2 2024
0:00 / 0:00
---
PHAT Stock 12 Month Forecast
Average Price Target
$22.00
▲(37.07% Upside)
Technical Analysis
Best Analysts Covering PHAT
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+25.50%
assigned a buy rating 11 months ago
Copying Sean Kim PhD's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +25.50% per trade.
---